Journal
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
Volume 43, Issue 5, Pages E702-E706Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MPH.0000000000001891
Keywords
AYA; comparison; discrepancy; event-free survival; Ewing sarcoma; pediatric; outcomes; overall survival
Categories
Ask authors/readers for more resources
Adolescent and young adult patients with Ewing sarcoma have inferior survival compared to pediatric patients, likely due to higher incidence of metastatic disease and larger tumors in AYA patients. Treatment-related differences do not appear to contribute significantly to the higher mortality among AYA patients.
Adolescent and young adult (AYA) patients with Ewing sarcoma have inferior survival compared with pediatric patients even when treated with similar regimens. Investigation into specific explanations is lacking. A retrospective chart review of Ewing sarcoma patients at a single institution was performed, and 104 patients were identified, 45 were 15 to 39 years of age (AYA cohort) and 59 younger than 15 years (pediatric cohort). AYA patients demonstrated more metastatic disease (50% vs. 24%, P=0.009), peripheral tumor location (64% vs. 41%, P=0.025), percentage of male patients (76% vs. 51%; P=0.010), and tumor size >= 5 cm (93% vs. 70%, P=0.016) than pediatric patients. Five-year overall survival was 77.7% and 53.0% and event-free survival was 68.7% and 40.6% for pediatric versus AYA, respectively. Similar rates of toxicity and chemotherapeutic dose adjustments were demonstrated. In this cohort, increased AYA patient mortality appears to be related to disease characteristics rather than treatment-related differences.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available